Company Interview / Cynata secures $8M funding

Dr Kilian Kelly CEO of Cynata Therapeutics (ASX:CYP) states that the company has secured over $8 million through an institutional placement. This funding attracts new institutional investors and will support ongoing clinical development, commercialisation activities, and manufacturing processes.

Kilian mentions Cynata's (ASX:CYP) successful phase one trial results for diabetic foot ulcers, noting its novel stem cell wound dressing yielded promising outcomes. Additionally, the company is progressing phase two and three trials for other conditions, with completion expected over the next 18 months.

Manufacturing is conducted in the US through a strategic partnership with Fujifilm. This collaboration aims to advance product trials and find commercial partners to bring their therapies to market. Cynata's robust cash position is anticipated to carry the company into mid-2026.